PULSE BIOSCIENCES, INC.

Trading Arrangements

During thethree months ended* September 30, 2026,*none of our directors or officers (as defined in Rule16a-1(f) under the Exchange Act) adopted or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement” as such terms are defined under Item408 of Regulation S-K.

Segment Reporting

As further discussed in Note 8 “Segment Reporting” of the Company’s footnotes to our condensed consolidated financial statements, included elsewhere in this Quarterly Report on Form 10-Q, the Company recast prior period significant expenses to conform with current period presentation. Previously facilities and IT costs were included within general and administration expenses. Beginning April 1, 2026, facilities and IT costs are allocated across the significant expense categories based on the methodology used within our GAAP income statement presentation. The recast of prior period information had no impact on the Company's condensed consolidated balance sheets, statements of operations, or statements of cash flows.

This information is intended to assist investors in making comparisons of the Company’s historical financial information with future financial information. The reported financial information below has been reclassified to conform to the current presentation.

The tables below summarizes the reclassified presentation of the Company’s segment reporting:

1. Adjusted cost of product revenue includes material costs, cash compensation costs, fees paid to consultants and outside service providers and organizations, and other expenses relating to manufacturing the Company’s commercial products. It does not include stock-based compensation, depreciation, amortization — see descriptions of Other segment items in footnote 7 below.

*2.*Cross platform research and engineering includes compensation costs, fees paid to consultants and outside service providers and organizations, prototype spending and other expenses relating to the acquisition, design and development of the Company’s clinical stage devices.

3. R&D manufacturing and engineering includes compensation costs, fees paid to consultants and outside service providers and organizations, and costs associated with the procurement of materials and the manufacturing of the Company’s clinical stage devices.

4. Clinical and regulatory includes compensation costs, fees paid to consultants and outside service providers and organizations, and costs associated with clinical trials and regulatory approvals required for the development of the Company’s clinical stage devices.

5. General and administrative includes compensation costs and fees paid to consultants and outside service providers and organizations in support of the administrative functions of the Company, including finance, legal, and human resources.

6. Sales and marketing includes compensation costs, fees paid to consultants and outside service providers and organizations, costs associated with marketing and sales strategy as well as execution of marketing and sales initiatives for the Company's products.

*7.*Other segment items includes stock-based compensation, depreciation and amortization.